OBJECTIVE: The present study addressed two questions: what fraction of individuals maintain a sustained high HIV-1 RNA load after the acute HIV-1C infection peak and how long is a high HIV-1 RNA load maintained after acute HIV-1C infection in this subpopulation? DESIGN/ METHODS: Plasma HIV-1 RNA dynamics were studied in 77 participants with primary HIV-1C infection from African cohorts in Gaborone, Botswana, and Durban, South Africa. HIV-infected individuals who maintained mean viral load of at least 100,000 (5.0 log(10)) copies/ml after 100 days postseroconversion (p/s) were termed extended high viremics. Individuals were followed longitudinally for a median [interquartile range (IQR)] of 573 (226-986) days p/s. RESULTS: The proportion of extended high viremics was 34% [95% confidence interval (CI) 23-44%] during the period 100-300 days p/s and 19% (95% CI 9-29%) over the period of 200-400 days p/s. The median (IQR) duration of HIV-1 RNA load at least 100,000 copies/ml among extended high viremics was 271 (188-340) days p/s. For the subset with average viral load at least 100,000 copies/ml during 200-400 days p/s, the median (IQR) duration was 318 (282-459) days. The extended high viremics had a significantly shorter time to CD4 cell decline to 350 cells/μl (median: 88 vs. 691 days p/s for those not designated as extended high viremics; P < 0.0001, Gehan-Wilcoxon test). CONCLUSION: A high proportion of extended high viremics - individuals maintaining high plasma HIV-1 RNA load after acute infection - have been identified during primary HIV-1 subtype C infection. These extended high viremics likely contribute disproportionately to HIV-1 incidence.
OBJECTIVE: The present study addressed two questions: what fraction of individuals maintain a sustained high HIV-1 RNA load after the acute HIV-1C infection peak and how long is a high HIV-1 RNA load maintained after acute HIV-1C infection in this subpopulation? DESIGN/ METHODS: Plasma HIV-1 RNA dynamics were studied in 77 participants with primary HIV-1C infection from African cohorts in Gaborone, Botswana, and Durban, South Africa. HIV-infected individuals who maintained mean viral load of at least 100,000 (5.0 log(10)) copies/ml after 100 days postseroconversion (p/s) were termed extended high viremics. Individuals were followed longitudinally for a median [interquartile range (IQR)] of 573 (226-986) days p/s. RESULTS: The proportion of extended high viremics was 34% [95% confidence interval (CI) 23-44%] during the period 100-300 days p/s and 19% (95% CI 9-29%) over the period of 200-400 days p/s. The median (IQR) duration of HIV-1 RNA load at least 100,000 copies/ml among extended high viremics was 271 (188-340) days p/s. For the subset with average viral load at least 100,000 copies/ml during 200-400 days p/s, the median (IQR) duration was 318 (282-459) days. The extended high viremics had a significantly shorter time to CD4 cell decline to 350 cells/μl (median: 88 vs. 691 days p/s for those not designated as extended high viremics; P < 0.0001, Gehan-Wilcoxon test). CONCLUSION: A high proportion of extended high viremics - individuals maintaining high plasma HIV-1 RNA load after acute infection - have been identified during primary HIV-1 subtype C infection. These extended high viremics likely contribute disproportionately to HIV-1 incidence.
Authors: Jaclyn K Wright; Vladimir Novitsky; Mark A Brockman; Zabrina L Brumme; Chanson J Brumme; Jonathan M Carlson; David Heckerman; Bingxia Wang; Elena Losina; Mopo Leshwedi; Mary van der Stok; Lungile Maphumulo; Nompumelelo Mkhwanazi; Fundisiwe Chonco; Philip J R Goulder; Max Essex; Bruce D Walker; Thumbi Ndung'u Journal: J Virol Date: 2011-02-02 Impact factor: 5.103
Authors: C L Celum; S P Buchbinder; D Donnell; J M Douglas ; K Mayer; B Koblin; M Marmor; S Bozeman; R M Grant; J Flores; H W Sheppard Journal: J Infect Dis Date: 2000-12-08 Impact factor: 5.226
Authors: F de Wolf; I Spijkerman; P T Schellekens; M Langendam; C Kuiken; M Bakker; M Roos; R Coutinho; F Miedema; J Goudsmit Journal: AIDS Date: 1997-12 Impact factor: 4.177
Authors: Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: S J Clark; M S Saag; W D Decker; S Campbell-Hill; J L Roberson; P J Veldkamp; J C Kappes; B H Hahn; G M Shaw Journal: N Engl J Med Date: 1991-04-04 Impact factor: 91.245
Authors: Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: G R Kaufmann; P Cunningham; A D Kelleher; J Zaunders; A Carr; J Vizzard; M Law; D A Cooper Journal: J Infect Dis Date: 1998-12 Impact factor: 5.226
Authors: Ujjwal Neogi; Amanda Häggblom; Kamalendra Singh; Leonard C Rogers; Shwetha D Rao; Wondwossen Amogne; Eugen Schülter; Maurizio Zazzi; Eddy Arnold; Stefan G Sarafianos; Anders Sönnerborg Journal: J Antimicrob Chemother Date: 2015-10-30 Impact factor: 5.790
Authors: Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker Journal: J Am Soc Nephrol Date: 2015-03-18 Impact factor: 10.121
Authors: Erin Kahle; Mary Campbell; Jairam Lingappa; Deborah Donnell; Connie Celum; Raphael Ondondo; Andrew Mujugira; Kenneth Fife; Nelly Mugo; Saidi Kapiga; James I Mullins; Jared M Baeten Journal: AIDS Date: 2014-01-14 Impact factor: 4.177
Authors: Vladimir Novitsky; Melanie Prague; Sikhulile Moyo; Tendani Gaolathe; Mompati Mmalane; Etienne Kadima Yankinda; Unoda Chakalisa; Refeletswe Lebelonyane; Nealia Khan; Kathleen M Powis; Erik Widenfelt; Simani Gaseitsiwe; Scott L Dryden-Peterson; Molly Pretorius Holme; Victor De Gruttola; Pam Bachanas; Joseph Makhema; Shahin Lockman; M Essex Journal: AIDS Res Hum Retroviruses Date: 2018-01-17 Impact factor: 2.205
Authors: Susan A Fiscus; Susan Cu-Uvin; Abel Tilahun Eshete; Michael D Hughes; Yajing Bao; Mina Hosseinipour; Beatriz Grinsztejn; Sharlaa Badal-Faesen; Joan Dragavon; Robert W Coombs; Ken Braun; Laura Moran; James Hakim; Timothy Flanigan; N Kumarasamy; Thomas B Campbell Journal: Clin Infect Dis Date: 2013-03-26 Impact factor: 9.079